araag2/HINT huggingface dataset:
Clinical trial NCT01736514 (phase 3, status: completed)
Conditions: gout
ICD codes: M10.9, M10.08, M10.00, M10.011, M10.012, M10.019, M10.021
Drugs: febuxostat, allopurinol
SMILES: CC(C)COC1=C(C=C(C=C1)C1=NC(C)=C(S1)C(O)=O)C#N, O=C1N=CN=C2NNC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects will also have a history or presence of gout as defined by the American
             College of Rheumatology (ACR) criteria

          -  Subject has serum urate level >= 8.0 mg/dL at the screening Visit

        Exclusion Criteria:

          -  Female subject who is breast-feeding or pregnant

          -  Subject has a history of xanthinuria

          -  Subject who is intolerant of allopurinol, ie hypersensitivity, Steven-Johnson
             syndrome/topic epidermal necrolysis

          -  Subject who takes allopurinol > 300 mg/day and with serum urate level > 8mg/dL

          -  Subject who is HLA B*5801 positive

          -  Subject who is receiving thiazide diuretic therapy

          -  Subject who has secondary hyperuricemia

          -  Subject who requires concurrent therapy with any systemic or topical medications,
             prescribed or non-prescribed, containing aspirin or other salicylates (low doses of
             aspirin will be allowed(ie. =< 325mg/day)

          -  Subject who requires therapy with prednisone > 10 mg/ day during the study

          -  Subject who has active liver disease or hepatic dysfunction, defined as both ALT and
             AST > 1.5 times the upper limit of normal

          -  Subject who has serum creatinine >= 1.5mg/dL

          -  Subject who has any another significant medical condition as defined by the
             investigator that would interfere with the treatment, safety or compliance with the
             protocol (eg. A clinically significant ECG result)

          -  Subject who has a history of cancer (other than basal cell carcinoma of the skin)
             within 5 years prior to the study, or has taken any systemic cancer chemotherapy
             within 5 years prior to the study

          -  Subject who has previously participated in a clinical study in which febuxostat was
             administered

          -  Subject who has participated in another investigational trial within the 30 days prior
             to the study
Clinical trial NCT00415623 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: amlodipine, amlodipine
SMILES: COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=C1, COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Untreated Hypertensive Patients: An systolic blood pressure of >=160 mmHg or diastolic
             blood pressure >=100mmHg.

          -  Treated Hypertensive Patients: An systolic blood pressure of >=140 mmHg or diastolic
             blood pressure of >= 90 mmHg.

          -  Patients with insufficient response to 5 mg of amlodipine in the screening period:Two
             successive systolic blood pressure measurements at Visit 4 (Week -2) and Visit 5 (Week
             0 = baseline) >=140 mmHg

          -  Patients with a screening treatment compliance rate >= 80%

        Exclusion Criteria:

          -  Subjects with secondary hypertension (renal disease, pheochromocytoma, and Cushing's
             syndrome, etc.), severe hypertension (systolic blood pressure of 180 mmHg or higher,
             or diastolic blood pressure of 110 mmHg or higher), and malignant hypertension
Clinical trial NCT00139880 (phase 3, status: completed)
Conditions: parkinson's disease
ICD codes: G20
Drugs: parcopa
SMILES: C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Stable Parkinson's disease

        Exclusion Criteria:

          -  idiopathic PD with Hoehn and Yahr state II or III
Clinical trial NCT01586364 (phase 3, status: completed)
Conditions: atrophy, vaginal diseases
ICD codes: H21.29, H31.23, H47.20, H47.22, N50.0, N64.2, N90.5
Drugs: ospemifene 60mg oral tablet
SMILES: OCCOC1=CC=C(C=C1)C(=C(\CCCl)C1=CC=CC=C1)\C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Postmenopausal women aged 40 to 80 years with a diagnosis of vulvar and vaginal
             atrophy (VVA) as assessed by vaginal pH, maturation index of vaginal smear, and
             self-reported symptoms at Baseline for Protocol 15-50310

          -  Did not have a uterus

          -  Met the inclusion and exclusion criteria for Protocol 15-50310

          -  Had completed Protocol 15-50310 without any clinically significant abnormal findings
             at the end-of-study visit for Protocol 15-50310

          -  Provided written informed consent to participate in the study and agreed to follow
             dosing instructions and complete all required study visits

        Exclusion Criteria:

          -  Had clinically significant abnormal findings at the Week 12 End of Study visit for
             Protocol 15-50310

          -  Had any physical or mental condition which, in the opinion of the investigator, may
             have interfered with the subject's ability to comply with the study procedures
Clinical trial NCT01353469 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin human/insuman comb 25 (hr1799), insulin human/novolin® 30r
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion criteria:

          -  Type 2 diabetes mellitus patients, as defined by World Health Organization (WHO),
             diagnosed for at least 1 year at the time of screening visit who are under premix
             insulin therapy, with or without oral anti-diabetic drug (OAD)

          -  Signed written informed consent

        Exclusion criteria:

          -  HbA1c <7% or HbA1c >10% at screening

          -  No self-monitoring of blood glucose within 3 months prior to screening visit

          -  Premix insulin treatment for less than 3 months. Insulins other than premix insulin
             treatment within 3 months prior to screening visit

          -  In case of treatment with OAD, treatment with a stable OAD dose and regimen for less
             than 3 months prior to screening visit

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT00408421 (phase 3, status: completed)
Conditions: osteoarthritis knee pain
ICD codes: M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019
Drugs: duloxetine, placebo
SMILES: CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female outpatients with osteoarthritis knee pain.

        Exclusion Criteria:

          -  Cardiovascular, hepatic, renal, respiratory, or hematologic illness, or other medical
             or psychiatric condition that, in the opinion of the investigator, would compromise
             participation or be likely to lead to hospitalization during the course of the study.

          -  Acute liver injury (such as hepatitis) or severe cirrhosis.

          -  Previous exposure to duloxetine.

          -  Body Mass Index (BMI) over 40.

          -  Major depressive disorder.

          -  Daily use of narcotics.
Clinical trial NCT01127217 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: amlodipine/losartan, amlodipine
SMILES: CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1, COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  18 aged or over

          -  Patients with blood pressure measured at Visit 1; MSSBP≤180mmHg and MSDBP≤110 mmHg if
             on anti-hypertensive drugs, 160mmHg≤MSSBP≤199mmHg and 80mmHg≤MSDBP≤119mmHg if not on
             anti-hypertensive drugs

          -  Patients with blood pressure measured at Visit 2 were 160mmHg≤MSSBP≤199mmHg and
             80mmHg≤MSDBP≤119mmHg

        Exclusion Criteria:

          -  Inability to stop all prior anti-hypertensive drugs safely during wash out period of 3
             to 7 days

          -  ≥ sitSBP 20mmHg or ≥ sitDBP 10mmHg of variation in three measurements from the
             reference arm selected at Screening

          -  History of hypersensitivity to dihydropyridines, angiotensin II receptor blockers or
             thiazide diuretics

          -  Secondary hypertension or suspected to be

          -  Continuously took medicinal drugs that might affect blood pressure rather than
             anti-hypertensive drugs more than 3 months

          -  Type 2 diabetes mellitus which is not controlled or with type 1 diabetes mellitus

          -  History of severe neurovascular disease, severe heart disease

          -  Known as moderate or malignant retinopathy.

          -  Renal diseases; serum creatinine ≥ 2mg/dl

          -  Hepatic diseases; increase in ALT or AST ≥ 2xUNL

          -  Anuria

          -  Hyponatremia/hypokalemia or hypercalcemia

          -  Active Gout

          -  Surgical or medical diseases which might significantly change ADME of medicines

          -  History of malignant tumor

          -  Autoimmune diseases

          -  History of alcohol or drug abuse

          -  Positive to pregnancy test, nursing mother, woman with an intention of pregnancy

          -  Considered inappropriate to participate in the clinical trial with any reason, based
             on investigator's decision

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT01097018 (phase 3, status: completed)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: capecitabine, perifosine, placebo
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have failed available therapy for the treatment of advanced colorectal
             cancer, including fluoropyrimidine, irinotecan, oxaliplatin, bevacizumab and for K-ras
             wild-type (WT) patients, anti-EGFR antibody (cetuximab or panitumumab) containing
             therapies.

          -  For oxaliplatin-based therapy, failure of therapy will also include patients who had
             oxaliplatin discontinued secondary to toxicity.

          -  No prior exposure to capecitabine in the metastatic colorectal cancer setting, except
             limited-course radiosensitizing capecitabine

          -  Patients must have at least one measurable lesion by RECIST criteria

        Exclusion Criteria:

          -  Patients with known dipyrimidine dehydrogenase (DPD) deficiency or prior severe
             reaction to 5-FU